Home › Funds › Catalys Pacific, LLC › MLYS
Catalys Pacific, LLC position in MLYS
Mineralys Therapeutics, Inc. · Health Care
Catalys Pacific, LLC reported holding 7,799,518 shares of MLYS (Mineralys Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$196.0M, representing 93.45% of its reported portfolio and ranking #1 among its reported holdings. Catalys Pacific, LLC has disclosed MLYS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-10-30 · Source: SEC EDGAR Form 13F-HR
How Catalys Pacific, LLC's MLYS position evolved
Catalys Pacific, LLC first disclosed a stake in MLYS in Q4 2023 at 9,194,579 shares (US$79.1M). The position peaked in Q3 2025 at 8,903,838 shares, worth US$337.6M. Across 12 filings, Catalys Pacific, LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 7,799,518 shares valued at US$196.0M — a reduction of -104,320 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 9.19M | $79.07M | New |
| Q1 2024 | 9.19M | $118.70M | Hold |
| Q2 2024 | 9.19M | $107.58M | Hold |
| Q3 2024 | 8.64M | $104.69M | Reduce |
| Q4 2024 | 8.64M | $106.41M | Hold |
| Q1 2025 | 8.90M | $141.39M | Add |
| Q2 2025 | 8.90M | $120.47M | Hold |
| Q3 2025 | 8.90M | $337.63M | Hold |
| Q4 2025 | 7.90M | $286.83M | Reduce |
| Q1 2026 | 7.90M | $214.11M | Hold |
| Q2 2026 | 7.90M | $213.25M | Hold |
| Q3 2026 | 7.80M | $196.00M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLYS and 13F data
MLYS (Mineralys Therapeutics, Inc.) is a Health Care company. 53 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Samsara BioCapital, LLC (US$158.4M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$106.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLYS
- RA CAPITAL MANAGEMENT, L.P. 7.69M sh · $207.55M · Q2 2026
- Samsara BioCapital, LLC 5.87M sh · $158.40M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M sh · $106.79M · Q2 2026
- Laurion Capital Management LP 2.51M sh · $67.62M · Q2 2026
- ORBIMED ADVISORS LLC 2.11M sh · $56.94M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 1.56M sh · $42.20M · Q2 2026
- Andera Partners 1.59M sh · $40.00M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.47M sh · $39.66M · Q2 2026
- Ghisallo Capital Management LLC 1.12M sh · $30.35M · Q2 2026
- Logos Global Management LP 1.05M sh · $28.33M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.04M sh · $28.06M · Q2 2026
- Davern Capital Partners, LP 858.75K sh · $23.17M · Q2 2026
More on Catalys Pacific, LLC
FAQ
How long has Catalys Pacific, LLC held MLYS?
Catalys Pacific, LLC has disclosed MLYS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Catalys Pacific, LLC's current position in MLYS?
As of Q3 2026, Catalys Pacific, LLC holds 7.80M shares of MLYS (Mineralys Therapeutics, Inc.), valued at $196.00M, representing 93.45% of its reported portfolio and ranking #1.
Has Catalys Pacific, LLC been buying or selling MLYS?
In the latest 13F filing (Q3 2026), Catalys Pacific, LLC reduced its position in MLYS. The position peaked in Q3 2025 at 8.90M shares.
Which other funds hold MLYS?
Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Samsara BioCapital, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.